Oral Presentations - Guzman 307
Inhibition of Breast Cancer Cell Proliferation by Diarylthiourea Analog, SL1-18
Location
Guzman 307
Start Date
4-24-2015 1:40 PM
End Date
4-24-2015 1:55 PM
Student Type
Graduate
Faculty Mentor(s)
Maggie Louie, Ph.D.
Presentation Format
Oral Presentation
Abstract/Description
Breast cancer is the most common malignancy that occurs in women in the US and has the second highest cancer-associated mortality rate. Depending on the expression of estrogen receptor α (ERα), breast cancer can be classified as ER positive or negative. Current drugs used to treat ER+ cancers include selective estrogen receptor modulators (SERMs) and selective estrogen receptor down-regulators (SERDs). Unfortunately, prolonged exposure to these drugs often leads to the development of acquired resistance. Consequently, there is a great need to develop alternative therapeutic options. Flexible heteroarotinoids (Flex-Hets) are groups of compounds that are derived from retinoids. Flex-Hets have been shown to display anti-cancer activity and low toxicity in comparison to the retinoid precursor. The objective of this study is to investigate the anti-cancer effects of SL1-18 — a novel heteroarotinoid— on breast cancer. Our data suggest that treatment of MCF-7 with SL1-18 inhibit the cell growth with a GI50 of 5mM. In order to understand the mechanism of action, we evaluated the effects of SL1-18 on the expression of cell cycle regulators and our results suggest that SL1-18 decreases the expression of cyclin A, cyclin B, cyclin D1 and cdk2. Furthermore, cell cycle analysis revealed that SL1-18 reduces the number of cells going through the S phase when compared to mock-treated controls. Taken together, these preliminary results suggest that the SL1-18 may be a potent inhibitor of breast cancer cell growth, but further research is necessary to determine its mechanism of action.
Inhibition of Breast Cancer Cell Proliferation by Diarylthiourea Analog, SL1-18
Guzman 307
Breast cancer is the most common malignancy that occurs in women in the US and has the second highest cancer-associated mortality rate. Depending on the expression of estrogen receptor α (ERα), breast cancer can be classified as ER positive or negative. Current drugs used to treat ER+ cancers include selective estrogen receptor modulators (SERMs) and selective estrogen receptor down-regulators (SERDs). Unfortunately, prolonged exposure to these drugs often leads to the development of acquired resistance. Consequently, there is a great need to develop alternative therapeutic options. Flexible heteroarotinoids (Flex-Hets) are groups of compounds that are derived from retinoids. Flex-Hets have been shown to display anti-cancer activity and low toxicity in comparison to the retinoid precursor. The objective of this study is to investigate the anti-cancer effects of SL1-18 — a novel heteroarotinoid— on breast cancer. Our data suggest that treatment of MCF-7 with SL1-18 inhibit the cell growth with a GI50 of 5mM. In order to understand the mechanism of action, we evaluated the effects of SL1-18 on the expression of cell cycle regulators and our results suggest that SL1-18 decreases the expression of cyclin A, cyclin B, cyclin D1 and cdk2. Furthermore, cell cycle analysis revealed that SL1-18 reduces the number of cells going through the S phase when compared to mock-treated controls. Taken together, these preliminary results suggest that the SL1-18 may be a potent inhibitor of breast cancer cell growth, but further research is necessary to determine its mechanism of action.
Comments
This abstract was submitted to the American Association for Cancer Research, AACR conference 2015.